Clinical Trial Update: JS001 Combination Therapy in NSCLC Negative Driving Gene After First-line Chemotherapy. [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for JS001 in combination therapy for non-small cell lung cancer after first-line chemotherapy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• JS001 (PD-1 inhibitor)

Snippet

Sponsor: Li Zhang, MD | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: UNKNOWN